Chris Cameron, PhD
Chief Scientific Officer
Expertise:
Dr. Chris Cameron is a global thought leader in health economics and outcomes research with over a decade of experience. Prior to joining EVERSANA, Chris was a partner at Cornerstone Research Group Inc., and lead of Health Economics at CADTH. He has also been a consultant decision scientist for ICER, a member of the Economic Guidance Panel at pCODR, and served on PMPRB Technical Panel on drug pricing guidelines in Canada. Chris is an adjunct (scholar) professor at Dalhousie University, and has authored over 100 peer-reviewed publications in many of the world’s top journals, including JAMA, Lancet, and BMJ. His research has been featured in the Globe and Mail and New York Times. He was recently named one of the most prolific authors in the world on indirect treatment comparisons, and was a co-author on the PRISMA NMA reporting guidelines.
Chris holds a bachelor’s degree in Mathematics and an MSc and PhD in Epidemiology where he was a Vanier Canada Graduate Scholar. He also completed a fellowship on real-world data analytics at Harvard University and FDA’s Sentinel Initiative, and the Oxford Artificial Intelligence Programme.
Articles by Chris Cameron, PhD
A Review of Indirect Treatment Comparisons (ITCs) in Regulatory Approval, Reimbursement and Pricing Recommendations for Oncology Drugs
The use of indirect treatment comparisons (ITCs) has increased significantly in recent years, particularly in the assessment of oncology and rare diseases where direct head-to-head trials may be impractical or unavailable, with numerous oncology and orphan drug submissions incorporating ITCs to support regulatory decisions and health technology assessment (HTA) recommendations. The Value & Evidence team at EVERSANA (Krista Tantakoun, Christopher Olsen, Fatemeh Mirzayeh Fashami, Imtiaz Samjoo and Chris Cameron), in collaboration with Dr. Brian Hutton, professors at Kyoto University and Yokohama City University School of Medicine in Japan, and colleagues at Janssen Pharmaceutical, critically reviewed and synthesized assessment documents for oncology drug submissions that included ITCs from various regulatory bodies […]
RWEsearch 2024 | Innovating Clinical Trial Design with Real World Evidence
At the RWEsearch Annual Summit 2024, hosted by Healthark Insights, Chris Cameron, Chief Scientific Officer at EVERSANA, emphasized that advancements in Real World Evidence will accelerate with ongoing learning and use of technology and AI.
Evolving Standards: NICE’s Enhanced RWE Framework for Global Data Transportability
The National Institute for Health and Care Excellence (NICE) has updated its real-world evidence (RWE) framework published in June 2022. The framework guides the planning, conduct and reporting of RWE studies, with the objective of improving the quality and transparency of evidence. The framework has been updated to include guidance on external validity bias and the transportability of international data. The framework includes updates/additions to the following sections: External validity: A new section has been added that defines the external validity of study findings in terms of generalizability and transportability. This includes having the analytical sample represent the target population and accounting for differences in patient or disease characteristics, healthcare […]
The Integral Role of Global Indirect Treatment Comparison in Europe’s JCA
Discover the integral role of Global Indirect Treatment Comparison (ITC) Programs in Europe’s Joint Clinical Assessment (JCA) in this insightful piece by EVERSANA. Learn why a global ITC program is not just beneficial but essential for market access and health technology assessment (HTA) submissions. The article delves into the mission of the JCA and the imperative of a global ITC program, especially in areas where direct comparisons are not feasible. It also provides a blueprint for achieving excellence in a global ITC program, emphasizing early engagement, strategic partnerships and analytical depth. EVERSANA’s HEOR team, with its experience in conducting 400+ ITC analyses and launching 20+ global ITC programs, emerges as […]
The AI Revolution in HEOR: How ChatGPT-4o and Multi-AI Agents Are Shaping the Future
Discover the future of Health Economics and Outcomes Research (HEOR) in our article, ‘The AI Revolution in HEOR’. Learn how AI, particularly ChatGPT-4o, is transforming the field with its enhanced speed and capabilities. Explore the potential of multi-AI agents in augmenting HEOR workflows and the emerging role of AI in supporting core HEOR services. This article also delves into the leadership skills required for managing AI agents and the AI-first approach of EVERSANA. Don’t miss out on this insightful read. Complete the form to download the full article.
A Review of Worldwide Indirect Treatment Comparison (ITC) Guidelines and Best Practices
Considering the challenges of conducting head-to-head clinical trials, indirect treatment comparisons (ITCs) offer valuable insights into clinical effectiveness that reflect current and local practices. These insights can help regulators and reimbursement agencies make better-informed decisions, thereby facilitating patient access to novel treatments. Recent methodological advancements in ITCs have led to the release of regional, national and global guidelines outlining jurisdiction-specific methodology and reporting recommendations and/or best practices. The Value & Evidence team at EVERSANA (Krista Tantakoun, Christopher Olsen, Fatemeh Mirzayeh Fashami, Imtiaz Samjoo and Chris Cameron), in collaboration with Dr. Brian Hutton, professors at Kyoto University and Yokohama City University School of Medicine in Japan, and colleagues at Janssen Pharmaceutical, […]
Decoding EMA’s Blueprint on Real-World Evidence
The European Medicines Agency (EMA) has published a document that elaborates on the application of Real-World Data (RWD) in evaluating human medicines. This document succinctly outlines the utility of Real-World Evidence (RWE), which is derived from RWD analysis, within the scope of regulatory decision-making. It details the types of studies that can be conducted, how the EMA can pinpoint optimal resources to address research inquiries, and the procedure for requesting RWD studies. Here are the three pivotal findings from the EMA report on RWE: RWE Generation Pathways: The EMA has delineated three principal avenues for RWE production: the Data Analysis and Real World Interrogation Network (DARWIN EU), in-house electronic health […]
Understanding ICER’s 2024 Protocol for Assessing Unsupported Price Increases on Prescription Drugs
Understanding ICER’s 2024 Protocol for Assessing Unsupported Price Increases on Prescription Drugs The Institute for Clinical and Economic Review (ICER) has recently updated its protocol for assessing unsupported price increases of prescription drugs. This initiative provides a transparent and systematic approach to evaluate whether substantial price hikes in medications in the United States are justified by new clinical evidence or other valid factors. Key Points of the ICER 2024 Unsupported Price Increases Protocol: Scope of Review: The 2024 Unsupported Price Increases report will focus on up to 13 drugs that have experienced significant price increases over a one-year period. Criteria for Selection: Drugs are selected based on net sales revenue, exceeding the […]
Empowering Success: EVERSANA’s Value & Evidence Team Guides Clients Through CMS Drug Negotiations Under the Inflation Reduction Act
Authors: Chris Cameron, Kerise Clarke, Barkha Patel, Amanda Griffin In anticipation of CMS’s announcement of the first 10 drugs to be selected for negotiations through the Inflation Reduction Act on September 1, 2023, we partnered to support our clients as they faced the prospect of selection. Our engagement began well before the announcement date to help them assess their readiness for participation and their risk of being included, supported by evidence-generation plans to cover any potential data gaps. This proactive approach not only equipped our clients with a realistic understanding of the challenges they might face but also ensured they were well-prepared for the scrutiny and demands of the program, […]
What EVERSANA’s Growing Abstract Count at ISPOR U.S. Means to the HEOR Industry
EVERSANA’s Value & Evidence (V&E) and Data & Analytics (D&A) team collectively had an impressive 27 abstracts accepted to ISPOR U.S. 2023, showcasing EVERSANA’s ability to cross-solve for clients’ HEOR needs. EVERSANA’s Value & Evidence and Data & Analytics teams have had 27 abstracts accepted to ISPOR U.S. 2023, the leading global conference for health economics and outcomes research (HEOR). Chris Cameron, PhD, EVERSANA’s Chief Scientific Officer, and others will be on-site and are looking forward to connecting. Learn more about the event and schedule a meeting with EVERSANA today! Chris Cameron, PhD, Chief Scientific Officer, EVERSANA How did your team manage to produce such a high volume of abstracts […]
ISPOR 2020 WORKSHOP: Developing Global Indirect Treatment Comparison Programs for Market Access
DEVELOPING AND IMPLEMENTING AN INDIRECT TREATMENT COMPARISON (ITC) PROGRAM TO SUPPORT GLOBAL HEALTH TECHNOLOGY ASSESSMENT (HTA) AND REIMBURSEMENT SUBMISSIONS Virtual ISPOR 2020 | WEDNESDAY, May 20th, 2020 | 10:00 AM ET PURPOSE: This interactive workshop will examine the various indirect comparison methodologies that are available. Commonly used ITC methods such as network meta-analysis (NMA) and matching-adjusted indirect comparisons (MAIC) will be discussed using real-world case studies. Discussion leaders and international experts in ITC from Canada, US and Europe will describe methods to develop and implement global ITC strategies to support HTA and reimbursement submissions. The workshop will also provide guidance on selecting the appropriate ITC method to align with analytic objectives […]
ISPOR 2020 PODIUM: PSM and Bayesian Hierarchical Design Methods to Integrate Single-Arm Studies into NMAs in Lung Cancer
APPLICATION OF PROPENSITY SCORE MATCHING AND BAYESIAN HIERARCHICAL DESIGN METHODS TO INTEGRATE SINGLE-ARM STUDIES INTO NETWORK META-ANALYSES (NMAS): Opportunities and Pitfalls Illustrated in a Case Study Assessing Ablation/Radiation Therapies in Lung Cancer Virtual ISPOR 2020 | TUESDAY, May 19th, 2020 | 5:45-6:00 PM ET OBJECTIVES: Network meta-analyses (NMAs) generally include direct comparative evidence from randomized controlled trials (RCTs) and/or comparative observational studies; however, comparative evidence is limited in many disease/treatment areas. The objective of this analysis was to discuss opportunities and pitfalls associated with incorporating single-arm studies into NMAs, illustrated in a case study assessing the effectiveness of ablation/radiation therapies in lung cancer. METHODS: A systematic literature review was conducted […]
ISPOR 2020 PODIUM: Methodological Challenges with NMAs Assessing Long-term Efficacy in Psoriasis
METHODOLOGICAL CHALLENGES WITH CONDUCTING NETWORK META-ANALYSES ASSESSING LONG-TERM COMPARATIVE EFFICACY IN PSORIASIS- A CRITIQUE OF ASSUMPTIONS UNDERPINNING RECENT INDIRECT TREATMENT COMPARISONS Virtual ISPOR 2020 | TUESDAY, May 19th, 2020 | 5:30-5:45 PM ET OBJECTIVES: In network meta-analysis (NMA) of psoriasis trials, cross-over after an initial placebo-controlled period limits the connectivity of long-term evidence networks. We illustrate the challenges with conducting NMAs assessing efficacy beyond cross-over in psoriasis by critically appraising the assumptions underpinning recent long-term NMAs. METHODS: We compared three recent NMA studies (Armstrong et al. 2019, Sawyer et al. 2018, and Diels et al. 2017) assessing long-term (beyond 16 to 24 weeks) comparative efficacy in psoriasis and investigated how the three […]